Prestige Brands debuts alergy relief gel
IRVINGTON, N.Y. Prestige Brands Holdings is introducing a new kind of therapy for allergy relief across its Chloraseptic and Little Allergies brand families, to be called Allergen Block, Mark Pettie, Prestige chairman and chief executive officer, shared in a recent analyst call.
“There are two clear advantages to this patented innovative technology as compared with current allergy relief products,” he noted. “First, it works outside the body to help prevent allergy symptoms rather than relieve them once they’ve occurred. And second, they’re drug-free, making it appealing not only to current category users but non-users as well.”
Pettie reported that retailer authorizations have been strong as category managers prepare their stores for the coming cough/cold season. “Strong introductory support will begin with a national PR campaign later this month [August] and advertising is scheduled to start in September as retail distribution gains critical mass.”
The product works by creating an electrostatic field that shields a person’s nose from allergens. Suggested retail price is $14.99.
Kleenex improves tissues with extra soothing power
DALLAS, Texas Kimberly-Clark Corporation has announced a North American launch of Kleenex Facial Tissue with Lotion.
The addition to the Kleenex brand lineup boasts a lotion added to enhance the softness of each tissue. Kleenex also said that the new 3-ply tissue is 17 percent stronger than the company’s prior tissue with lotion.
Kim Underhill, president of the North American Family Care Business arm of Kimberly-Clark said, “Kleenex is the leading facial tissue brand because it consistently meets or exceeds consumers’ needs by delivering new innovations to the marketplace. Our newest facial tissue innovation combines a more soothing feeling with the strength desired by so many consumers.”
Kimberly-Clark has said that it plans other brand product line extensions into 2009.
Nutrition 21: study finds chromium picolinate reduces hunger
PURCHASE, N.Y. A new clinical study finding chromium picolinate, the active ingredient in Nutrition 21’s Chromax, significantly reduced food intake, hunger levels and fat cravings in overweight adult women, the company announced Thursday.
According to Nutririon 21, this is the first study to examine whether chromium picolinate affects food intake in humans. Study participants who took chromium picolinate while significantly reducing their caloric intake did not report increased hunger levels. Conversely, those participants on placebo who did not reduce their caloric intake to as great an extent as the chromium picolinate users, reported increased hunger levels.
These study findings suggest that chromium picolinate may impact the brain activity involved in signaling and possibly sustaining satiety levels during dieting.